MCID: THY025
MIFTS: 50

Thymus Cancer malady

Categories: Cancer diseases, Rare diseases, Immune diseases, Endocrine diseases, Genetic diseases

Aliases & Classifications for Thymus Cancer

Aliases & Descriptions for Thymus Cancer:

Name: Thymus Cancer 12 41 14
Thymic Carcinoma 12 56 52 14 69
Malignant Thymoma 12 56
Thymus Neoplasms 42 69
Malignant Neoplasm of Thymus 69
Neoplasm of Thymus 12
Thymoma, Malignant 12
Thymoma, Familial 69
Thymic Neoplasm 12
Thymoma, Type C 69
Thymic Tumor 12

Characteristics:

Orphanet epidemiological data:

56
thymic carcinoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:3277 DOID:3284
ICD10 33 C37
ICD9CM 35 164.0
NCIt 47 C4962 C7612
Orphanet 56 ORPHA99868
UMLS via Orphanet 70 C0205969 C1322286
ICD10 via Orphanet 34 C37

Summaries for Thymus Cancer

MedlinePlus : 41 the thymus is a small organ in your upper chest, under your breastbone. before birth and during childhood, the thymus helps the body make a type of white blood cell. these cells help protect you from infections. cancer of the thymus is rare. you are more likely to get it if you have other diseases such as myasthenia gravis, lupus or rheumatoid arthritis. sometimes there are no symptoms. other times, thymus cancer can cause a cough that doesn't go away chest pain trouble breathing doctors use a physical exam, imaging tests, and a biopsy to diagnose thymus cancer. the most common treatment is surgery to remove the tumor. other options include radiation therapy, chemotherapy, and hormone therapy. nih: national cancer institute

MalaCards based summary : Thymus Cancer, also known as thymic carcinoma, is related to thymus squamous cell carcinoma and thymoma, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Thymus Cancer is CD5 (CD5 Molecule), and among its related pathways/superpathways are Developmental Biology and Pathways in cancer. The drugs Prednisone and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include thymus and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and endocrine/exocrine gland

Disease Ontology : 12 A thymus cancer that derives from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found.

Related Diseases for Thymus Cancer

Diseases related to Thymus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
id Related Disease Score Top Affiliating Genes
1 thymus squamous cell carcinoma 31.6 EGFR SYP TP53
2 thymoma 31.4 CALB2 KRT7 MUC1 SYP
3 lymphoepithelioma-like thymic carcinoma 12.0
4 thymoma, familial 11.2
5 immunodeficiency with thymoma 11.0
6 thymus adenocarcinoma 10.9
7 thymus adenosquamous carcinoma 10.9
8 invasive malignant thymoma 10.8
9 noninvasive malignant thymoma 10.8
10 epithelial malignant thymoma 10.8
11 tibial aplasia ectrodactyly hydrocephalus 10.3 CD5 KIT
12 monkeypox 10.3 CD5 KIT SYP
13 rectum leiomyoma 10.3 KIT SMUG1 SYP
14 sebaceous adenoma 10.3 KIT MUC1 SYP
15 kidney clear cell sarcoma 10.3 EGFR KIT NKX2-1
16 bone marrow cancer 10.3 MUC1 NKX2-1 SYP
17 kidney disease 10.3 NKX2-1 SYP TP53
18 fragile x-associated tremor/ataxia syndrome 10.3 KIT SYP TP53
19 bone deterioration disease 10.3 NKX2-1 SYP TP53
20 congenital muscular dystrophy with hyperlaxity 10.3 MUC1 NKX2-1 SYP
21 precursor t-lymphoblastic lymphoma/leukemia 10.3 EGFR KIT MUC1
22 postpartum depression 10.3 KIT SMUG1 TP53
23 porokeratosis 10.3 MUC1 NKX2-1 TP53
24 wolffian adnexal neoplasm 10.3 EGFR TP53
25 arthus reaction 10.3 KIT SYP TP53
26 spasmodic dysphonia 10.3 KRT7 NKX2-1 SYP
27 prolactin producing pituitary tumor 10.3 KRT5 MUC1 SYP
28 paternal uniparental disomy of chromosome 1 10.3 EGFR SYP TP53
29 mitochondrial complex ii deficiency 10.3 NKX2-1 POMC SYP
30 early-onset parkinson disease 10.3 POMC SMUG1 SYP
31 choriocarcinoma of ovary 10.3 KIT KRT5 TP53
32 reactive arthritis 10.3 EGFR KIT TP53
33 tabes dorsalis 10.3 MUC1 SYP TP53
34 brain stem ependymoma 10.3 SMUG1 SYP
35 agenesis and aplasia of uterine body 10.3 EGFR KRT7 NKX2-1
36 chronic monocytic leukemia 10.3 EGFR SMUG1 TP53
37 ovarian germ cell teratoma 10.3 CD5 KIT SMUG1 SYP
38 extragonadal seminoma 10.3 CD5 CD8A SMUG1
39 childhood brain germinoma 10.3 MUC1 SYP TP53
40 brachial plexus neoplasm 10.2 CALB2 TP53
41 bone benign neoplasm 10.2 POMC SYP TP53
42 paraphimosis 10.2 KRT7 SYP TP53
43 prostate lymphoma 10.2 KRT5 KRT7 SMUG1
44 myxedema 10.2 EGFR SMUG1 TP53
45 uterine corpus endometrial stromal sarcoma 10.2 KRT7 SMUG1 TP53
46 epidermolysis bullosa simplex, recessive 1 10.2 KIT KRT5 POMC
47 vaginal villous adenoma 10.2 KRT7 MUC1 SYP
48 laryngeal mucoepidermoid carcinoma 10.2 KRT5 KRT7 MUC1
49 pancreatic agenesis 10.2 EGFR KIT NKX2-1 SYP
50 syndromic x-linked intellectual disability 10.2 KIT KRT5 POMC

Graphical network of the top 20 diseases related to Thymus Cancer:



Diseases related to Thymus Cancer

Symptoms & Phenotypes for Thymus Cancer

Human phenotypes related to Thymus Cancer:

56 32 (show all 25)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 56 32 Occasional (29-5%) HP:0012378
2 dyspnea 56 32 Frequent (79-30%) HP:0002094
3 chest pain 56 32 Frequent (79-30%) HP:0100749
4 hyperhidrosis 56 32 Occasional (29-5%) HP:0000975
5 weight loss 56 32 Occasional (29-5%) HP:0001824
6 palpebral edema 56 32 Frequent (79-30%) HP:0100540
7 cough 56 32 Frequent (79-30%) HP:0012735
8 mediastinal lymphadenopathy 56 32 Very frequent (99-80%) HP:0100721
9 fatigable weakness 56 32 Occasional (29-5%) HP:0003473
10 diaphragmatic paralysis 56 32 Frequent (79-30%) HP:0006597
11 neoplasm of the thymus 56 32 Very frequent (99-80%) HP:0100521
12 abnormality of the vena cava 56 32 Frequent (79-30%) HP:0005345
13 edema 56 Frequent (79-30%)
14 headache 32 HP:0002315
15 ptosis 32 HP:0000508
16 dysphagia 32 HP:0002015
17 increased intracranial pressure 32 HP:0002516
18 immunodeficiency 32 HP:0002721
19 abnormal bleeding 32 HP:0001892
20 autoimmunity 32 HP:0002960
21 neuroendocrine neoplasm 32 HP:0100634
22 pericarditis 32 HP:0001701
23 cardiac arrest 32 HP:0001695
24 dysgammaglobulinemia 32 HP:0002961
25 language impairment 32 HP:0002463

GenomeRNAi Phenotypes related to Thymus Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.83 POMC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.83 KIT PIK3R2 POMC DNTT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.83 PIK3R2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.83 PIK3R2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.83 DNTT
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.83 POMC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.83 DNTT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.83 DNTT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.83 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.83 KIT DNTT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.83 DNTT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.83 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.83 DNTT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.83 DNTT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.83 PIK3R2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.83 POMC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.83 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.83 POMC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.83 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.83 PIK3R2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.83 DNTT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.83 PIK3R2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.83 KIT PIK3R2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.83 POMC
25 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.83 POMC KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.83 KIT

MGI Mouse Phenotypes related to Thymus Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.97 TP53 AKT3 AMPH CD8A EGFR KIT
2 nervous system MP:0003631 9.97 AKT3 AMPH CALB2 CD5 CD8A DPYSL5
3 neoplasm MP:0002006 9.86 POMC SMUG1 TP53 AKT3 EGFR KIT
4 no phenotypic analysis MP:0003012 9.56 CD5 EGFR KIT KRT5 NKX2-1 POMC
5 normal MP:0002873 9.32 AKT3 CALB2 CD5 CD8A DNTT EGFR

Drugs & Therapeutics for Thymus Cancer

Drugs for Thymus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
2
Azathioprine Approved Phase 4 446-86-6 2265
3 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
6 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
7 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
8 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
9 glucocorticoids Phase 4,Phase 3,Phase 2
10 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
11 Hormones Phase 4,Phase 3,Phase 2,Phase 1
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
13
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
17
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
18
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
19
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
20
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
21
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
22
Mycophenolate mofetil Approved, Investigational Phase 2, Phase 3 128794-94-5 5281078
23
Mycophenolic acid Approved Phase 2, Phase 3 24280-93-1 446541
24
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
25 Liver Extracts Phase 3,Phase 1,Phase 2
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
27 Etoposide phosphate Phase 3,Phase 2,Phase 1
28 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
29 Alkylating Agents Phase 2, Phase 3,Phase 1
30 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1
31 Adjuvants, Anesthesia Phase 3
32 Analgesics Phase 3,Phase 2,Phase 1
33 Analgesics, Opioid Phase 3
34 Anesthetics Phase 3
35 Anesthetics, General Phase 3
36 Anesthetics, Intravenous Phase 3
37 Central Nervous System Depressants Phase 3
38 Narcotics Phase 3
39 pancreatic polypeptide Phase 3
40 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
41 Methylprednisolone acetate Phase 3,Phase 2
42 Methylprednisolone Hemisuccinate Phase 3,Phase 2
43 Prednisolone acetate Phase 3,Phase 2
44 Prednisolone hemisuccinate Phase 3,Phase 2
45 Prednisolone phosphate Phase 3,Phase 2
46 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
47 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 1
48 Antifungal Agents Phase 2, Phase 3,Phase 1
49 Anti-Infective Agents Phase 2, Phase 3,Phase 1
50 Cola Nutraceutical Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 108)
id Name Status NCT ID Phase
1 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Active, not recruiting NCT00987116 Phase 4
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3
4 Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
5 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3
6 TBI Dose De-escalation for Fanconi Anemia Recruiting NCT00352976 Phase 2, Phase 3
7 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2
8 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2
9 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2
10 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2
11 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2
12 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2
13 Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Completed NCT00332969 Phase 2
14 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2
15 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2
16 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
17 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2
18 Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01369849 Phase 1, Phase 2
19 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2
20 High Dose Somatostatin Analogues in Neuroendocrine Tumors Completed NCT00990535 Phase 2
21 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2
22 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
23 Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma Completed NCT00967044 Phase 1, Phase 2
24 Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings Completed NCT00603954 Phase 2
25 Rapamycin and Regulatory T Cells in Kidney Transplantation Completed NCT01014234 Phase 2
26 Allogeneic Transplantation From Related Haploidentical Donors Completed NCT00185692 Phase 2
27 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Recruiting NCT02220855 Phase 2
28 Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma Recruiting NCT02636556 Phase 2
29 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2
30 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2
31 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2
32 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Recruiting NCT02629419 Phase 2
33 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
34 Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies Recruiting NCT03094832 Phase 1, Phase 2
35 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2
36 The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor Recruiting NCT02317224 Phase 2
37 Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. Recruiting NCT02698410 Phase 2
38 Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation Recruiting NCT01081405 Phase 2
39 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome Recruiting NCT00001849 Phase 1, Phase 2
40 Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Active, not recruiting NCT01301391 Phase 2
41 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2
42 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2
43 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2
44 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2
45 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Active, not recruiting NCT01011439 Phase 2
46 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting NCT01802320 Phase 2
47 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Active, not recruiting NCT01964924 Phase 2
48 MK-3475 in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2
49 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Active, not recruiting NCT02623127 Phase 2
50 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial Active, not recruiting NCT01563354 Phase 2

Search NIH Clinical Center for Thymus Cancer

Cochrane evidence based reviews: thymus neoplasms

Genetic Tests for Thymus Cancer

Anatomical Context for Thymus Cancer

MalaCards organs/tissues related to Thymus Cancer:

39
Thymus, Testes

Publications for Thymus Cancer

Articles related to Thymus Cancer:

id Title Authors Year
1
Sunitinib effective for rare thymus cancer. ( 25680712 )
2015
2
Gene mutation may signal indolent thymus cancer. ( 25185203 )
2014
3
Thymus cancer epidemiology in England and Wales. ( 2372494 )
1990

Variations for Thymus Cancer

Cosmic variations for Thymus Cancer:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM133763 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 9

Expression for Thymus Cancer

Search GEO for disease gene expression data for Thymus Cancer.

Pathways for Thymus Cancer

Pathways related to Thymus Cancer according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 AKT3 DPYSL5 EGFR KIT KRT5 KRT7
2 12.52 AKT3 EGFR KIT PIK3R2 TP53
3 12.41 AKT3 EGFR KIT PIK3R2 TP53
4
Show member pathways
12.35 AKT3 EGFR MUC1 PIK3R2 TP53
5
Show member pathways
12.3 AKT3 EGFR KIT PIK3R2
6
Show member pathways
12.27 AKT3 EGFR KIT PIK3R2 PSMB11 TP53
7
Show member pathways
12.16 AKT3 EGFR PIK3R2 TP53
8 12.14 AKT3 EGFR PIK3R2 TP53
9
Show member pathways
12.01 AKT3 EGFR PIK3R2 TP53
10
Show member pathways
11.88 AKT3 EGFR PIK3R2 TP53
11 11.82 AKT3 EGFR PIK3R2 TP53
12
Show member pathways
11.78 EGFR PIK3R2 TP53
13
Show member pathways
11.76 AKT3 EGFR PIK3R2 TP53
14 11.74 AKT3 EGFR PIK3R2
15 11.71 AKT3 PIK3R2 TP53
16
Show member pathways
11.71 AKT3 EGFR KIT PIK3R2 TP53
17
Show member pathways
11.69 AKT3 KIT PIK3R2
18 11.68 KRT5 POMC TP53
19 11.67 AKT3 EGFR PIK3R2 TP53
20 11.62 EGFR PIK3R2 TP53
21 11.61 AKT3 PIK3R2 TP53
22 11.59 AKT3 CD8A PIK3R2
23 11.54 CD5 CD8A DNTT KIT
24 10.83 AKT3 EGFR KIT PIK3R2 TP53

GO Terms for Thymus Cancer

Biological processes related to Thymus Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cerebral cortex cell migration GO:0021795 9.16 EGFR NKX2-1
2 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.13 EGFR KIT PIK3R2
3 phosphatidylinositol-mediated signaling GO:0048015 8.92 EGFR KIT PIK3R2 TP53

Molecular functions related to Thymus Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 EGFR PIK3R2 TP53
2 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR KIT
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.8 EGFR KIT PIK3R2

Sources for Thymus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....